Hub : Traits :

Alzheimer’s Disease (in father)

14 significantly associated models · 11 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 11 85421392 86026808 1 1 2.1e-09 8.0e-08 4.6e-01 98 PICALM
2 19 44190626 46680895 10 11 2.7e-30 8.3e-193 2.4e-22 89 APOC1 APOC1P1 APOC2 APOE CEACAM19 ERCC1 PVRL2 TOMM40 ZNF285

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder or Schizophrenia 1.26 1 0 0.0 0.00 1.0e+00 APOC2
Alzheimer’s Disease (in mother) 109.41 9 8 17.8 0.99 4.6e-09 APOC1 APOC1P1 APOC2 APOE CEACAM19 PICALM PVRL2 TOMM40 ZNF285
Alzheimer’s Disease (including proxy) 265.00 9 9 20.0 0.99 2.6e-10 APOC1 APOC1P1 APOC2 APOE CEACAM19 PICALM PVRL2 TOMM40 ZNF285
HDL Cholesterol 3.33 3 0 0.0 0.00 1.0e+00 APOC1 APOE PVRL2
LDL Cholesterol 36.39 7 5 11.1 0.10 8.3e-01 APOC1 APOE CEACAM19 ERCC1 PVRL2 TOMM40 ZNF285
Primary Biliary Cirrhosis 1.55 1 0 0.0 0.00 1.0e+00 APOE
Triglycerides 15.93 6 4 8.9 0.29 5.8e-01 APOC1 APOC2 APOE PVRL2 TOMM40 ZNF285
Blood Eosinophil Count 1.94 4 3 6.7 -0.97 3.2e-02 APOC1 APOC2 APOE TOMM40
Blood Platelet Count 2.24 6 2 4.4 -0.30 5.6e-01 APOC1 APOE ERCC1 PICALM PVRL2 ZNF285
Blood Red Count 0.58 3 0 0.0 0.00 1.0e+00 APOE PICALM PVRL2
Blood White Count 2.70 6 4 8.9 -0.59 1.3e-01 APOC1 APOC1P1 APOE ERCC1 PVRL2 TOMM40
Heel T-Score 0.25 1 0 0.0 0.00 1.0e+00 ZNF285
BMI 1.54 5 1 2.2 -0.98 2.3e-03 APOC1P1 CEACAM19 PVRL2 TOMM40 ZNF285
Height 1.06 7 4 8.9 -0.06 8.9e-01 APOC1 APOC1P1 APOC2 APOE CEACAM19 PICALM TOMM40
Waist Hip Ratio (WHR) 1.44 3 0 0.0 0.00 1.0e+00 APOC1 APOE PICALM
Systolic Blood Pressure 1.45 4 0 0.0 0.08 9.2e-01 APOC1 APOC1P1 APOE PVRL2
Allergy or Eczema 1.73 1 0 0.0 0.00 1.0e+00 PVRL2
Cardiovascular Disease 3.47 5 1 2.2 0.43 4.7e-01 APOC1P1 APOE ERCC1 PVRL2 ZNF285
Type 2 Diabetes (T2D) (2018) 1.62 1 0 0.0 0.00 1.0e+00 APOC1
Lung FVC 1.03 2 0 0.0 0.00 1.0e+00 PVRL2 TOMM40
Chronotype (morning person) 1.37 1 0 0.0 0.00 1.0e+00 ZNF285
Hair Pigment 0.21 1 0 0.0 0.00 1.0e+00 TOMM40
Hand grip strength (left) 2.73 4 0 0.0 -0.56 2.5e-01 APOC1P1 PICALM PVRL2 TOMM40
Relative age of first facial hair 2.48 3 0 0.0 0.00 1.0e+00 APOC1P1 PICALM TOMM40
Vitamin and mineral supplements 0.91 1 0 0.0 0.00 1.0e+00 PVRL2
Medication: Metformin 2.72 2 0 0.0 0.00 1.0e+00 APOC1 APOE
Diabetes (mother) 3.38 2 0 0.0 0.00 1.0e+00 APOC1 PVRL2
Leg fat-free mass (left) 0.99 2 0 0.0 0.00 1.0e+00 APOC1P1 APOC2
Trunk fat percentage 1.02 2 0 0.0 0.00 1.0e+00 APOC1P1 PVRL2
Hand grip strength (right) 2.77 4 0 0.0 -0.51 3.1e-01 APOC1P1 PICALM PVRL2 TOMM40
Average weekly fortified wine intake 7.25 2 1 2.2 -0.21 7.9e-01 APOC1P1 TOMM40
High blood pressure 0.98 2 0 0.0 0.00 1.0e+00 APOC1 APOE
Hayfever, allergic rhinitis or eczema 1.60 1 0 0.0 0.00 1.0e+00 PVRL2
Sitting height 0.67 3 0 0.0 0.00 1.0e+00 APOC1 APOE PICALM
Chronic bronchitis/emphysema (father) 1.77 1 0 0.0 0.00 1.0e+00 PICALM
High blood pressure (mother) 2.78 2 0 0.0 0.00 1.0e+00 APOE TOMM40
Body mass index (BMI) 1.16 2 0 0.0 0.00 1.0e+00 APOC1P1 PVRL2
Leg predicted mass (left) 0.99 2 0 0.0 0.00 1.0e+00 APOC1P1 APOC2
Trunk fat mass 1.29 2 0 0.0 0.00 1.0e+00 APOC1P1 PVRL2
Waist circumference 1.38 3 0 0.0 0.00 1.0e+00 APOC1P1 PVRL2 TOMM40
Nervous feelings 1.82 1 0 0.0 0.00 1.0e+00 TOMM40
Forced vital capacity (FVC) 1.03 1 0 0.0 0.00 1.0e+00 PVRL2
Mouth/teeth dental problems 1.62 1 0 0.0 0.00 1.0e+00 PVRL2
Diabetes (self-reported) 2.52 2 0 0.0 0.00 1.0e+00 APOC1 APOE
Medication: Ramipril 1.97 1 0 0.0 0.00 1.0e+00 APOE
Medication: Simvastatin 6.43 5 1 2.2 0.50 3.9e-01 APOE CEACAM19 ERCC1 PVRL2 ZNF285
Weight 1.52 3 1 2.2 0.00 1.0e+00 APOC1P1 PVRL2 TOMM40
Arm fat percentage (right) 1.02 2 0 0.0 0.00 1.0e+00 APOC1P1 PVRL2
Trunk fat-free mass 1.21 2 1 2.2 0.00 1.0e+00 APOC1P1 APOC2
Hip circumference 1.12 3 0 0.0 0.00 1.0e+00 APOC1P1 APOE PVRL2
Alcohol intake versus 10 years previously 0.92 1 0 0.0 0.00 1.0e+00 ERCC1
Father's age at death 2.11 1 0 0.0 0.00 1.0e+00 ERCC1
Worrier / anxious feelings 1.14 1 0 0.0 0.00 1.0e+00 APOC1P1
Forced expiratory volume in 1-second (FEV1) 1.22 2 0 0.0 0.00 1.0e+00 PVRL2 TOMM40
Medication: Cholesterol lowering 5.01 3 1 2.2 0.00 1.0e+00 CEACAM19 PVRL2 ZNF285
Illnesses of mother 4.31 2 0 0.0 0.00 1.0e+00 APOC1P1 ZNF285
Forced expiratory volume in 1-second (FEV1), Best measure 0.97 1 0 0.0 0.00 1.0e+00 PVRL2
Arm fat mass (right) 1.34 3 0 0.0 0.00 1.0e+00 APOC1P1 PVRL2 TOMM40
Trunk predicted mass 1.17 2 1 2.2 0.00 1.0e+00 APOC1P1 APOC2
Standing height 0.81 6 0 0.0 0.02 9.7e-01 APOC1 APOC1P1 APOC2 APOE CEACAM19 PICALM
Breastfed as a baby 1.40 1 0 0.0 0.00 1.0e+00 ERCC1
Loud music exposure frequency 4.50 2 0 0.0 0.86 1.4e-01 APOC1P1 TOMM40
Medication for cholesterol, blood pressure or diabetes 1.34 1 0 0.0 0.00 1.0e+00 PVRL2
Birth weight 1.72 2 0 0.0 0.00 1.0e+00 APOC1P1 TOMM40
Forced vital capacity (FVC), Best measure 1.09 1 0 0.0 0.00 1.0e+00 PVRL2
Body fat percentage 1.08 2 0 0.0 0.00 1.0e+00 APOC1P1 PVRL2
Leg fat percentage (right) 1.22 3 0 0.0 0.00 1.0e+00 APOC1P1 PVRL2 TOMM40
Arm fat-free mass (right) 1.10 2 0 0.0 0.00 1.0e+00 APOC1P1 APOC2
Shortness of breath walking on level ground 1.65 1 0 0.0 0.00 1.0e+00 ZNF285
Heart disease (mother) 1.94 1 0 0.0 0.00 1.0e+00 APOC1
Reproduciblity of spirometry measurement using ERS/ATS criteria 1.71 1 0 0.0 0.00 1.0e+00 CEACAM19
Whole body fat mass 1.38 3 0 0.0 0.00 1.0e+00 APOC1P1 PVRL2 TOMM40
Leg fat mass (right) 1.51 3 0 0.0 0.00 1.0e+00 APOC1P1 PVRL2 TOMM40
Arm predicted mass (right) 0.96 1 0 0.0 0.00 1.0e+00 APOC1P1
Comparative height size at age 10 0.94 1 0 0.0 0.00 1.0e+00 APOC1P1
Supplements: Vitamin C 2.55 1 0 0.0 0.00 1.0e+00 PVRL2
Knee pain experienced in last month 1.52 1 0 0.0 0.00 1.0e+00 PICALM
Hypertension (Self-reported) 0.90 2 0 0.0 0.00 1.0e+00 APOC1 APOE
Illnesses of siblings: Diabetes 2.39 2 0 0.0 0.00 1.0e+00 APOC1 APOE
Forced expiratory volume in 1-second (FEV1), predicted 1.34 3 0 0.0 0.00 1.0e+00 APOC1 APOE CEACAM19
Whole body fat-free mass 1.13 2 1 2.2 0.00 1.0e+00 APOC1P1 APOC2
Leg fat-free mass (right) 0.97 2 0 0.0 0.00 1.0e+00 APOC1P1 APOC2
Arm fat percentage (left) 0.99 2 0 0.0 0.00 1.0e+00 APOC1P1 PVRL2
Diabetes diagnosed by doctor 3.17 2 0 0.0 0.00 1.0e+00 APOC1 APOE
Mouth/teeth dental problems: Mouth ulcers 2.22 1 0 0.0 0.00 1.0e+00 TOMM40
Medication for cholesterol 2.08 1 0 0.0 0.00 1.0e+00 PVRL2
Illnesses of father: None of the above (group 1) 4.98 2 0 0.0 -0.11 8.9e-01 APOC1P1 TOMM40
Forced expiratory volume in 1-second (FEV1), predicted percentage 1.26 1 0 0.0 0.00 1.0e+00 PVRL2
Whole body water mass 1.10 2 1 2.2 0.00 1.0e+00 APOC1P1 APOC2
Leg predicted mass (right) 0.97 2 0 0.0 0.00 1.0e+00 APOC1P1 APOC2
Arm fat mass (left) 1.27 2 0 0.0 0.00 1.0e+00 APOC1P1 PVRL2
High cholesterol (Self-reported) 12.69 7 2 4.4 0.67 1.0e-01 APOC1P1 APOC2 APOE CEACAM19 ERCC1 PVRL2 ZNF285
Medication: Atorvastatin 4.48 2 1 2.2 0.00 1.0e+00 PVRL2 ZNF285
Basal metabolic rate 1.24 2 1 2.2 0.00 1.0e+00 APOC1P1 APOC2
Leg fat percentage (left) 1.36 3 0 0.0 0.00 1.0e+00 APOC1P1 PVRL2 TOMM40
Arm fat-free mass (left) 1.30 3 1 2.2 0.00 1.0e+00 APOC1P1 APOC2 TOMM40
Vascular/heart problems diagnosed by doctor 1.09 2 0 0.0 0.00 1.0e+00 APOC1 APOE
Cholesterol lowering medication 7.59 5 1 2.2 0.96 8.5e-03 APOC1P1 CEACAM19 ERCC1 PVRL2 ZNF285
Pack years of smoking 2.03 1 0 0.0 0.00 1.0e+00 TOMM40
Impedance of whole body 0.45 1 0 0.0 0.00 1.0e+00 APOC1P1
Leg fat mass (left) 1.61 3 0 0.0 0.00 1.0e+00 APOC1P1 PVRL2 TOMM40
Arm predicted mass (left) 1.29 3 1 2.2 0.00 1.0e+00 APOC1P1 APOC2 TOMM40

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 0 0.000 1.09
GTEx Adipose Visceral Omentum 1 0.049 1.12
GTEx Adrenal Gland 0 0.000 1.13
GTEx Artery Aorta 0 0.000 1.06
GTEx Artery Coronary 0 0.000 1.09
GTEx Artery Tibial 0 0.000 1.07
GTEx Brain Caudate basal ganglia 0 0.000 0.98
GTEx Brain Cerebellar Hemisphere 0 0.000 1.12
GTEx Brain Cerebellum 0 0.000 1.05
GTEx Brain Cortex 0 0.000 1.04
GTEx Brain Frontal Cortex BA9 0 0.000 1.10
GTEx Brain Hippocampus 0 0.000 1.07
GTEx Brain Hypothalamus 0 0.000 1.15
GTEx Brain Nucleus accumbens basal ganglia 0 0.000 1.10
GTEx Brain Putamen basal ganglia 0 0.000 1.15
GTEx Breast Mammary Tissue 0 0.000 1.08
GTEx Breast Mammary Tissue (Male) 0 0.000 1.10
GTEx Breast Mammary Tissue (Female) 0 0.000 1.09
GTEx Cells EBV-transformed lymphocytes 0 0.000 1.06
GTEx Cells Transformed fibroblasts 0 0.000 1.06
GTEx Colon Sigmoid 0 0.000 1.10
GTEx Colon Transverse 0 0.000 1.13
GTEx Esophagus Gastroesophageal Junction 0 0.000 1.10
GTEx Esophagus Mucosa 0 0.000 1.11
GTEx Esophagus Muscularis 0 0.000 1.11
GTEx Heart Atrial Appendage 0 0.000 1.07
GTEx Heart Left Ventricle 0 0.000 1.08
GTEx Liver 0 0.000 1.15
GTEx Lung 0 0.000 1.08
GTEx Muscle Skeletal 0 0.000 1.09
GTEx Nerve Tibial 1 0.023 1.09
GTEx Ovary 0 0.000 0.99
GTEx Pancreas 0 0.000 1.11
GTEx Pituitary 0 0.000 1.11
GTEx Prostate 0 0.000 1.05
GTEx Skin Not Sun Exposed Suprapubic 1 0.041 1.14
GTEx Skin Sun Exposed Lower leg 0 0.000 1.08
GTEx Small Intestine Terminal Ileum 0 0.000 1.06
GTEx Spleen 0 0.000 1.10
GTEx Stomach 0 0.000 1.07
GTEx Testis 0 0.000 1.09
GTEx Thyroid 1 0.025 1.12
GTEx Uterus 0 0.000 1.04
GTEx Vagina 0 0.000 1.17
GTEx Whole Blood 0 0.000 1.09
METSIM Adipose 0 0.000 1.06
NTR Blood 0 0.000 1.09
ROSMAP Brain Pre-frontal Cortex 0 0.000 1.09
YFS Blood 0 0.000 1.08
CommonMind Brain Pre-frontal Cortex 0 0.000 1.07
The Cancer Genome Atlas Bladder Urothelial Carcinoma 0 0.000 1.07
The Cancer Genome Atlas Breast Invasive Carcinoma 0 0.000 1.08
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 0 0.000 1.06
The Cancer Genome Atlas Colon Adenocarcinoma 0 0.000 1.07
The Cancer Genome Atlas Esophageal Carcinoma 0 0.000 1.18
The Cancer Genome Atlas Glioblastoma Multiforme 0 0.000 1.05
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 0 0.000 1.09
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 2 0.049 1.15
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 0 0.000 1.05
The Cancer Genome Atlas Brain Lower Grade Glioma 1 0.023 1.08
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 0 0.000 1.00
The Cancer Genome Atlas Lung Adenocarcinoma 0 0.000 1.12
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 2 0.080 1.18
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 0 0.000 1.08
The Cancer Genome Atlas Pancreatic Adenocarcinoma 0 0.000 1.13
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 0 0.000 1.06
The Cancer Genome Atlas Prostate Adenocarcinoma 1 0.022 1.11
The Cancer Genome Atlas Rectum Adenocarcinoma 0 0.000 1.11
The Cancer Genome Atlas Soft Tissue Sarcoma 0 0.000 1.10
The Cancer Genome Atlas Skin Cutaneous Melanoma 0 0.000 0.99
The Cancer Genome Atlas Stomach Adenocarcinoma 0 0.000 1.03
The Cancer Genome Atlas Testicular Germ Cell Tumors 1 0.078 1.10
The Cancer Genome Atlas Thyroid Carcinoma 2 0.039 1.09
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 1 0.195 1.18